WHAT DID THE PANEL RECOMMEND FOR FUTURE STUDIES?
There is a need to develop, standardize, and validate clinically relevant spasticity scales — for example, the Tardieu Spasticity Scale — that quantify spasticity according to its current definition. There is also an urgent need for studies to establish efficacy of the current therapies and find additional safer and effective treatments to help children affected by generalized spasticity due to CP. A first step could be to investigate medications that have shown antispasticity effect in adult patients, such as gabapentin. We also need to know more about long-term effects of these treatments and how they may improve function, ease of caregiving, and quality of life. DISCLOSURES Dr. Delgado has received research support from Abbott Labs, UCB Pharma, and Allergan and estimates that 2 percent of his clinical effort is spent on intrathecal baclofen trials and 20 percent on botulinum toxin injections. For a complete list of other panel members and their disclosures, see the original Jan. 26
Related Questions
- This company is not currently participating in the IC Pro coalition, but may choose to do so in the future (therefore, we recommend connecting this account). Whats IC Pro?
- Any one who lives in Minnesota.....what college would you recommend a future pediatrician?
- Is the longitudinal panel data available for Monitoring the Future?
